Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state

Heart and Lung: Journal of Acute and Critical Care

Volumn 43, Issue 3, 2014, Pages 262-263

  Stöllberger, Claudia ^a   Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

AF; Atrial fibrillation; DOAC; Drug interaction; Renal failure; Rivaroxaban; VKA

Indexed keywords

AMLODIPINE; DIGITOXIN; GLICLAZIDE; LISINOPRIL; MIRTAZAPINE; NEBIVOLOL; RIVAROXABAN; VALPROIC ACID;

AGE; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BODY HEIGHT; BODY MASS; BODY WEIGHT; CASE REPORT; CONFUSION; DIABETES MELLITUS; DYSPNEA; EPILEPTIC STATE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; PRIORITY JOURNAL; SPEECH DISORDER; TREATMENT DURATION; VERY ELDERLY; WEAKNESS;

ATRIAL FIBRILLATION; DRUG INTERACTION; RENAL FAILURE; RIVAROXABAN;

AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; EPILEPSY; FEMALE; HEART FAILURE; HUMANS; MORPHOLINES; RENAL INSUFFICIENCY; STROKE; THIOPHENES; VALPROIC ACID;

EID: 84899694189     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2014.03.004     Document Type: Article

References (11)

1. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 36:883-891.
2. Prasad V., Kaplan R.M., Passman R.S. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis 2012, 33:199-208.
3. Hellwig T., Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?. Ann Pharmacother 2013, 47:1478-1487.
4. Kubitza D., Becka M., Roth A., Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. JClin Pharmacol 2013, 53:249-255.
5. Maccallum P.K., Mathur R., Hull S.A., et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open 2013, 3:e003343.
6. Carley B., Griesbach S., Larson T., Krueger K. Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting. Am J Cardiol 2014, 113:650-654.
7. Mueck W., Schwers S., Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013, 11:10.
8. Cerveny L., Svecova L., Anzenbacherova E., et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007, 35:1032-1041.
9. Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000, 17:1189-1197.
10. Owen J.R., Nemeroff C.B. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998, 7(suppl 1):24-32.
11. Yates S., Sarode R. Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects. Curr Opin Hematol 2013, 20:552-557.